FIELD: pharmaceutical agents.
SUBSTANCE: invention relates to solid pharmaceutical formulations for peroral administration useful in treatment of mild and moderately severe dementia such as Alzheimer's disease. Claimed formulation contains Rivastigmin or pharmaceutically acceptable salts thereof. Formulation represent gelatin capsule filled with pellet mixture or mixture of magnesium stearate with nonpareils, or matrix tablet.
EFFECT: preparation with controlled prolonged Rivastigmin release and improved tolerance.
3 cl, 5 ex, 15 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CONTROLLED-RELEASE COMPOSITIONS FOR ORAL USING | 2000 |
|
RU2281758C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
| THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT | 2006 |
|
RU2442574C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| MEDICINE CONTAINING 3-(3-DIMETHYLAMINE-1-ETHYL-2-METHYLPROPYL) PHENOL WITH PROLONGED RELEASE OF REACTANT | 2002 |
|
RU2325905C2 |
| SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING RIVASTIGMINE | 2016 |
|
RU2727721C2 |
| PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION OF ENTACAPONE OR ITS SALTS | 2009 |
|
RU2540465C2 |
| TERBINAFINE SOLID MEDICINAL FORMULATION FOR ORAL ADMINISTRATION | 2002 |
|
RU2298402C2 |
| SOLID MEDICINAL FORM OF MATRIX TYPE, WHICH HAS ANTI-INFLAMMATORY, ANALGESIC, FEBRIFUGAL ACTIVITY, WITH PROLONGED RELEASE AND METHOD OF ITS OBTAINING | 2007 |
|
RU2354358C1 |
